



VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China

May 7, 2019

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / [VistaGen Therapeutics](#) (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that [Shawn Singh, VistaGen's Chief Executive Officer](#), will present at the 2019 ChinaBio® Partnering Forum held at the Kerry Hotel Pudong in Shanghai, China, on Wednesday, May 8, 2019 at 3:00 p.m. China Standard Time.

For more information regarding the conference, or to schedule a one-on-one meeting with VistaGen's management team, please contact the Company's representative in China, Greg Scott, CEO of ChinaBio at Greg.Scott@ChinaBio.com.

About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. VistaGen's CNS pipeline includes three drug candidates with potential for at-home use, rapid-onset therapeutic benefits and exceptional safety.

For more information, please visit www.vistagen.com and connect with VistaGen on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Company Contact

Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact

Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Media Contact

Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com

SOURCE: VistaGen Therapeutics

Released May 7, 2019